This guide is educational, not a recommendation to use MOTS-c. It contains no dosing or treatment instructions. Sources checked November 5, 2026. No clinician review is claimed.
Does MOTS-c improve endurance, help with weight loss or work without exercise? Those questions often lead to the same collection of studies, even though the studies did very different things. Some measured a peptide already present in people's bodies. Others gave MOTS-c to mice. A human drug-development study tested a related molecule called CB4211.
The evidence is interesting, but it does not yet establish that administering MOTS-c improves human exercise performance or produces meaningful weight loss. A registered human MOTS-c trial now exists, so the familiar claim that there are “no human trials” also needs updating. Its results have not been posted.
What is MOTS-c?
MOTS-c is a short peptide, made of 16 amino acids, identified through research into mitochondrial DNA. Mitochondria help cells convert nutrients into usable energy; they also participate in signaling. The original 2015 study connected MOTS-c with metabolic signaling, including a cellular energy-sensing pathway called AMPK. Researchers also tested administered MOTS-c in mice. Lee and colleagues, 2015
Three terms make the research easier to follow:
- Endogenous MOTS-c is the peptide measured within the body, for example before and after exercise.
- Administered MOTS-c means researchers give the peptide as an intervention and then assess what happens.
- CB4211 is a distinct drug-development analogue based on MOTS-c. Findings for that modified molecule need to keep its name attached.
The distinction is essential when a headline says “studied in humans.” Measuring something in human blood is human research, but it does not tell us what happens when people receive it as a treatment.
Did the exercise study give MOTS-c to people?
The widely cited 2021 Nature Communications paper combined mouse experiments with a small human exercise study. In the human part, 10 young men exercised on a stationary bicycle. Investigators measured MOTS-c in muscle and blood around the exercise session. The men were not given MOTS-c. Reynolds and colleagues, 2021
The often-repeated 11.9-fold figure described a rise in muscle MOTS-c after exercise, not an 11.9-fold increase in human endurance. The paper's experiments in which administered MOTS-c improved physical performance involved mice.
That makes the human finding evidence about the body's response to exercise. It cannot establish that an injection reproduces exercise's benefits, improves a person's race time or replaces training. Translating a mouse intervention into a human performance claim requires a human intervention study with suitable comparisons and outcomes.
What about newer human research?
New papers still need the same basic question: what was the intervention?
A 2026 muscle-bioenergetics paper included human observations during one-legged exercise alongside experimental work on muscle metabolism. It reported a change in MOTS-c in fluid around the exercising muscle. Those human observations did not demonstrate a performance benefit from giving people the peptide. 2026 study
Another human randomized study examined heat treatment during a period of ankle immobilization and measured mitochondrial-derived peptides. The randomized intervention was heat versus sham treatment, not MOTS-c. A paper can be both a human trial and relevant to MOTS-c biology without being a trial of MOTS-c as a drug. Human immobilization study
This is why searching only for “MOTS-c human RCT” can produce an overly reassuring impression. Read the methods, not just the words in the title or search result.
Is a human trial of administered MOTS-c registered?
Yes. On November 5, 2026, ClinicalTrials.gov listed NCT07505745, sponsored by Hudson Biotech, as recruiting. It describes a randomized, placebo-controlled phase 2a study of investigational MOTS-c in adults with prediabetes and overweight or obesity, with estimated enrollment of 120. MOTS-MET registry record
Its listed primary outcomes concern insulin sensitivity and treatment-emergent adverse events. The record had no posted results when checked; its last posted update was April 1, 2026. Recruitment status and planned enrollment are registry information, not independent confirmation of how many people have received treatment.
This updates the research landscape without supplying an answer about effectiveness. A registered plan does not establish benefit, safety or regulatory approval. We did not identify a completed, published human efficacy trial of administered native MOTS-c in this source review. That is a dated assessment of the evidence found, not a claim that future studies cannot show a benefit.
Is MOTS-c proven for weight loss or insulin resistance?
The original metabolic research included cell experiments and mouse models of diet-related obesity and insulin resistance. Those findings provide reasons to investigate the peptide, but they do not establish a weight-loss treatment for humans. Original full report
The current native-MOTS-c trial is investigating insulin sensitivity in a selected population. Until results are available, its existence cannot support claims about pounds lost, diabetes prevention or benefits in otherwise healthy athletes. Even a future improvement in a laboratory measurement would need to be assessed alongside adverse effects and outcomes that matter to patients.
For comparison, our tesamorelin evidence guide shows how to interpret a peptide with published randomized human findings: the population, fat compartment and comparison still matter. Evidence for one peptide cannot fill the gaps for another.
Is CB4211 the same thing as MOTS-c?
No. CB4211 is a related analogue developed as a separate investigational drug. ClinicalTrials.gov lists its completed phase 1a/1b study, NCT03998514, with 88 participants across its study parts. Its main focus was safety and tolerability, with additional pharmacokinetic and exploratory metabolic assessments. CB4211 study record
The sponsor's 2021 presentation describes a four-week phase 1b comparison in people with obesity and fatty liver disease. Twenty-three were randomized; 20 completed the end-of-treatment assessments. It reported exploratory changes in liver enzymes and glucose and a trend in body weight. Liver fat fell in both groups. These were small, short-duration findings reported by the sponsor, not proof of a general weight-loss or exercise treatment. CohBar presentation filed with the SEC
The registry had no posted results when checked. Public sponsor reporting is a separate source; “no results posted” on a registry does not mean no public findings exist anywhere. Neither source justifies transferring CB4211's results or tolerability to products labeled MOTS-c.
What is known about safety and FDA status?
FDA's July 2026 compounding briefing states that neither MOTS-c free base nor MOTS-c acetate is a component of an FDA-approved drug. It describes substantial gaps in the information available to evaluate these substances. A compounding advisory review is not drug approval, and the briefing explains that a final agency determination follows the advisory process and completed reviews. FDA briefing
FDA's risk page identifies concerns about immune reactions and peptide impurities or characterization. Its statement that it had not identified human exposure data should be read as the agency's evidence assessment, not as proof that no trial has been registered. The registry record described above still provides no posted safety results. FDA compounding safety information
“Naturally occurring” does not establish that an administered product is safe. The body's own signaling, an investigational formulation and a commercially offered product are different contexts. An absence of well-characterized adverse-effect data leaves uncertainty; it is not evidence of an absence of harm.
Can athletes use it under anti-doping rules?
USADA states that MOTS-c is prohibited at all times under the World Anti-Doping Agency's metabolic-modulator rules. That is a sports-eligibility rule, not proof that the peptide improves performance. Athletes need to assess eligibility separately from the strength of a treatment claim. USADA's MOTS-c explanation
How to read claims about energy or results without exercise
An immediate feeling of energy, a personal gym record or an uncontrolled before-and-after account cannot isolate a treatment effect. Training, sleep, food intake, expectations and ordinary variation can change at the same time. The studies reviewed here do not establish that MOTS-c reliably produces immediate energy or substitutes for exercise.
For the next claim you encounter, check four things:
- Was MOTS-c actually administered, or only measured?
- Were the subjects people, mice or cells?
- Was the molecule native MOTS-c or CB4211?
- Are there completed results for the advertised outcome, or only a mechanism, registration or anecdote?
If you already keep peptide records, Jabful can help organize them. A log cannot establish whether an experimental treatment works or is safe. The tracker-selection guide explains how to evaluate record-keeping features without confusing them with clinical guidance.